SAN

83.32

+0.8%↑

MRK1

117.95

+0.04%↑

SHL.DE

43.91

+1.39%↑

ARGX

757.2

-0.24%↓

FRE

47.49

-1.27%↓

SAN

83.32

+0.8%↑

MRK1

117.95

+0.04%↑

SHL.DE

43.91

+1.39%↑

ARGX

757.2

-0.24%↓

FRE

47.49

-1.27%↓

SAN

83.32

+0.8%↑

MRK1

117.95

+0.04%↑

SHL.DE

43.91

+1.39%↑

ARGX

757.2

-0.24%↓

FRE

47.49

-1.27%↓

SAN

83.32

+0.8%↑

MRK1

117.95

+0.04%↑

SHL.DE

43.91

+1.39%↑

ARGX

757.2

-0.24%↓

FRE

47.49

-1.27%↓

SAN

83.32

+0.8%↑

MRK1

117.95

+0.04%↑

SHL.DE

43.91

+1.39%↑

ARGX

757.2

-0.24%↓

FRE

47.49

-1.27%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

19.86 3.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.74

Max

20.1

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+19.17% upside

Turustatistika
By TradingEconomics
Turukapital	-25M 882M
Eelmine avamishind	16.21
Eelmine sulgemishind	19.86

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2025, 23:58 UTC

Omandamised, ülevõtmised, äriostud

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11. dets 2025, 23:56 UTC

Tulu

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Tulu

Costco Same-Store Sales, Membership Fees Rose in 1Q

11. dets 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11. dets 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11. dets 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11. dets 2025, 23:31 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:35 UTC

Tulu

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11. dets 2025, 22:30 UTC

Tulu

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11. dets 2025, 22:05 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11. dets 2025, 21:39 UTC

Tulu

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11. dets 2025, 21:39 UTC

Tulu

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11. dets 2025, 21:38 UTC

Tulu

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11. dets 2025, 21:37 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11. dets 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11. dets 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Dexus Aiming for Long-Term Holding of A$50M in Fund

11. dets 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus: Third Party Investors to Contribute Remainder

11. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11. dets 2025, 21:25 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

19.17% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 19.17%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.